Skip to main content

Advertisement

Table 1 Baseline demographic and exposure profile of participants initially classified as Chronic Beryllium Disease (CBD) and Beryllium Sensitization (BeS), with and without those with COPD

From: Long-term follow-up of beryllium sensitized workers from a single employer

  BeS COPD in (n = 50) CBD COPD in (n = 22) P value BeS COPD out (n = 40) CBD COPD out (n = 20) P value
Age in years (s.d.) 44.2 (11.1) 47.8 (10.5) 0.20 42.6 (11.2) 46.7 (10.2) 0.17
Sex (%male) 78 77 0.95 73 80 0.53
Race (% white) 94 100 0.71 93 100 0.66
Smoking Status       
Non-smoker% 42 36   50 40  
Ex smoker % 20 36 0.32 18 40 0.16
Current smoker % 38 27   33 20  
Mean length from hire date to baseline evaluation in years (s.d) 12.4 (11.1) 13.7 (7.0) 0.60 11.6 (10.1) 14.3 (7.0) 0.28
Period of beryllium exposure in years (s.d) 15.6 (11.8) 18.0 (8.4) 0.41 15.1 (11.7) 18.7 (8.5) 0.22
Time from baseline to follow-up evaluation(s.d) 7.1 (3.0) 8.1 (3.4) 0.20 7.0 (3.0) 8.5 (3.4) 0.09
History of hay fever, asthma or eczema (% positive) 48 50 0.96 50 45 0.72
Pulmonary Function Tests       
FEV1 mean % predicted (s.d.) 89.3 (14.5) 86.2 (16.7) 0.43 92.6 (12.7) 89.1 (14.3) 0.33
FVC mean % predicted (s.d.) 96.1 (14.8) 88.8 (11.7) 0.04 97.9 (14.3) 89.6 (11.5) 0.03
FEV1/FVC mean % predicted (s.d) 92.8 (10.3) 95.0 (12.0) 0.44 95.6 (8.1) 97.0 (8.1) 0.52
DLCO mean % predicted (s.d.) 101.3 (16.1) 99.9 (23) 0.77 103.6 (14.2) 104.0 (20.1) 0.94
TLC mean %(predicted) (s.d.) 98.6 (14.6) 94.5 (14.5) 0.35 98.6 (14.3) 91.5 (12.0) 0.10
Clinical evidence of COPD N (%) 10 (20) 2 (9.1) 0.32    
  1. * 3 subjects initially eligible were excluded after record review as they did not meet study criteria